#United States #San Diego #Neurocrine Biosciences #Congenital Adrenal Hyperplasia #Crinecerfont

Neurocrine Biosciences Launches Phase 2 Clinical Study of Crinecerfont

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) has officially begun its Phase 2 clinical study aimed at evaluating the safety and tolerability of crinecerfont in pediatric patients aged from 3 months to under 4 years with classic congenital adrenal hyperplasia (CAH). This significant initiative, announced on July 1, 2026, marks an important step toward providing safer treatment options for this vulnerable group of children.

Crinecerfont, known in the market as CRENESSITY®, is already approved in the United States as an adjunctive treatment for individuals aged 4 and older, helping to regulate androgen levels in patients with classic CAH. According to Dr. Sanjay Keswani, Chief Medical Officer of Neurocrine Biosciences, this clinical study underscores the company’s commitment to explore crinecerfont as a possible alternative treatment that could decrease dependency on glucocorticoids, which have been the conventional therapeutic approach for children facing this serious condition.

Understanding Congenital Adrenal Hyperplasia (CAH)

Congenital adrenal hyperplasia is a genetic disorder that manifests shortly after birth, often leading to life-threatening adrenal crises due to adrenal insufficiency. It also results in excessive androgen production, posing additional health risks for affected children. Traditionally, high doses of glucocorticoids have been utilized to manage the condition, but they come with considerable side effects and health challenges, particularly for young patients undergoing crucial growth stages.

The new Phase 2 study will adopt an open-label, single-arm design, enrolling 20 participants who meet the eligibility criteria. Designed as a 24-week treatment period, the primary focus of the study is to assess the safety and tolerability of crinecerfont in this young demographic, while secondary objectives will look into its pharmacokinetic and pharmacodynamic effects on hormone biomarkers. The outcome of this study could pave the way for a supplemental New Drug Application, potentially widening the approved indications for crinecerfont to encompass patients younger than 4 years.

The Significance of Crinecerfont

Crinecerfont's mechanism is noteworthy: it is a selective oral antagonist of the corticotropin-releasing factor type 1 receptor (CRF1), which plays a critical role in regulating adrenocorticotropic hormone (ACTH) secretion. By targeting the root of the excess ACTH production, crinecerfont reduces the high levels of adrenal androgens without relying on glucocorticoids, thereby offering a more physiologic approach to treatment.

In 2024, crinecerfont received FDA approval, marking a notable advancement in therapies for classic CAH after more than seven decades. The introduction of crinecerfont signifies hope for better management of adverse effects associated with traditional glucocorticoid treatments that young patients often endure.

Ongoing Research and Future Directions

Neurocrine is simultaneously conducting a Phase 2 study in the European Union, which focuses on assessing the safety and tolerability of crinecerfont in even younger patients, from birth to under 2 years of age. These parallel studies reflect Neurocrine’s robust commitment to pediatric research, particularly when it comes to conditions like CAH that have historically lacked adequate therapeutic solutions for the youngest patient populations.

The anticipated results from these studies will be closely monitored, as they could significantly influence future guidelines and treatment strategies for CAH in children. The potential approval of crinecerfont to treat this vulnerable group of patients could open new therapeutic possibilities and reduce the long-term complications associated with glucocorticoid use.

In conclusion, the beginning of the Phase 2 study for crinecerfont by Neurocrine Biosciences represents a proactive approach to addressing a critical gap in treatment for pediatric patients suffering from classic CAH. As clinical development proceeds, both health care providers and families will be hopeful for positive outcomes that prioritize safety and improved health for children under 4 years of age confronted with this challenging condition.